辰欣药业：股东石四药拟减持不超过1%股份

Core Viewpoint - The major shareholder of Chenxin Pharmaceutical (603367.SH), Shijiazhuang Four Pharmaceutical Co., Ltd., plans to reduce its stake through centralized bidding, citing funding needs as the reason for the reduction [1] Summary by Relevant Sections Shareholder Reduction - Shijiazhuang Four Pharmaceutical Co., Ltd. intends to reduce its holdings by up to 4,527,000 shares, which represents no more than 1% of the company's total share capital [1] - The reduction period will commence 15 trading days after the announcement and will last for three months [1]